All research and analysis tagged under Deep Dives.
SoFi's bank charter has transformed its funding costs, member economics, and competitive moat. At $18 billion market cap with $2.7 billion in revenue and 9 million members, the Research Desk breaks down why this is the most underappreciated fintech story in the market.
Honeywell trades at 33.9x earnings with a $149 billion market cap, a 1.9% dividend yield, and four distinct business segments — each arguably worth more separately than together. The breakup thesis is gaining momentum.
From 5.3% to 11.2% operating margin in four years. Now the company is spending $131.8 billion in a single year. This is either the best capital allocation decision in tech history or a very expensive bet on demand that may not materialise.
Revenue has recovered past the Humira patent cliff to $61.2 billion, but net income stuck at $4.2 billion exposes the gap between top-line replacement and bottom-line recovery.
Merck's 40th KEYTRUDA indication and approaching MK-0616 FDA decision tell a story about the post-patent strategy that consensus models are underestimating.
Operating income has grown sixfold since 2022. The market still thinks it is buying a retailer.
While hardware and chip stocks spent April repricing trade war exposure, Netflix had no supply chain to worry about. The real question is whether the margin transformation from 17.8% to 29.5% in three years justifies a 40x multiple.
The 2028 patent cliff is the defining event for Merck's next decade. Tulisokibart, ADCs, and subcutaneous Keytruda are the three bets management is making.
Seven consecutive earnings beats, 41% operating margins, and the largest AI infrastructure buildout in big tech. The valuation does not reflect any of it.
Datadog's revenue hit $2.8 billion growing at 25%, with AI-native monitoring products already contributing 8% of new ARR. The platform consolidation thesis is playing out faster than expected.
Post-Kenvue spin-off, J&J is a pure pharmaceutical and medtech company. Revenue hit $91.7B with a 22% profit margin. The immunology pipeline alone could be worth $20B in peak sales.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.
The market still prices Amazon as a retailer. The financials say otherwise.
Pfizer's revenue has halved from its pandemic peak, but the oncology pipeline — anchored by a $43 billion Seagen acquisition — is the most ambitious portfolio rebuild in pharma history.
The Next Generation Air Dominance contract gives Boeing a $100B+ programme lifecycle and proof its engineering edge survives the MAX crisis — arriving just as the commercial recovery gains momentum.
Operating margins hit 11.2% in 2025, up from 2.4% in 2022. Now Amazon is spending more on infrastructure than any company in history. That tension defines the investment case.
The gross profit compression from 75% to 71% is $8 billion in forgone earnings. At $4.3 trillion, the question is whether that is the floor or the beginning.
With 79% gross margins, $1 billion in free cash flow, and a first-mover position in AI observability, Datadog is building the monitoring layer that every AI deployment needs.
With $4 billion in ARR, 78% gross margins, 120%+ net retention, and 75% of customers on 5+ modules, CrowdStrike is winning the cybersecurity platform consolidation war.
With 57.7% operating margins, $15 billion in net income, and a network moat that has defeated every fintech challenger, Mastercard at 25x forward earnings is a premium compounder at a fair price.
The world's largest healthcare company by revenue just posted a 2.7% profit margin on $447.6 billion in revenue. The Optum story is strong — but the insurance side is under pressure.
Free cash flow tripled in 2025. The market is still pricing in a distant second.
Revenue jumped 45% to $65.2 billion and FCF recovered from near-zero to $9 billion — but at 40.8x trailing earnings, has the market already priced in the miracle?
Revenue is compounding, margins are at historic highs, and the ad engine keeps beating estimates. The question is whether $70 billion in annual AI infrastructure spend is an investment or a bill that comes due.
Both companies generate enormous cash flow, but their strategies have diverged. Exxon is betting on production growth while Chevron prioritises returns. The data reveals a clear winner.
Lilly's revenue surged from $28.3 billion to $45.0 billion in two years on the back of Mounjaro and Zepbound. At 67x trailing earnings, the market is pricing perfection — and it might be right.
China generates roughly a third of ASML's revenue. A new House bill wants to cut that off. The EUV monopoly is real, but the valuation assumes a growth path that requires the China relationship to survive.
At 18x earnings, BHP is priced as a mature iron ore dividend stock. The Antamina deal, OZ Minerals integration, and Jansen potash build tell a different story.
Search, Cloud, and YouTube each independently justify a higher price. The market is selling them as a bundle.
Free cash flow fell 77% in 2025. That is not what you think it means.
Q1 2026 came in below consensus for the second consecutive quarter. The harder question is what a genuine Tesla recovery actually requires at a $1.4 trillion valuation.
The MI300 ramp drove a 15.9% Q4 earnings surprise. The harder question is whether the GPU share story holds at current margins.
Dominant platform, disciplined margins, aggressive buybacks. But at 38x earnings, the stock prices in almost everything going right.
The $91 billion capex programme is suppressing free cash flow, but the operating machinery underneath has never been stronger.
Seven consecutive earnings beats, 41% operating margins, and 13.7x EV/EBITDA. Something is mispriced.
The market prices Uber as a disruption target. The financial data and recent AV partnerships tell a different story.
Revenue hit $7.2B in 2025, up 9% year-over-year. Operating income fell 40%. At a $47B market cap, that divergence matters.
Revenue doubled. Operating margins cratered, then began recovering. In 2025, free cash flow nearly tripled. Here is what the numbers actually say.
Down 29% from its high, PLTR's fundamentals have never been stronger. The question is whether the valuation math can ever close the gap.
The only supplier of irreplaceable chip-making equipment just got 14% cheaper. The business did not.
From negative free cash flow to $9.5 billion in four years. The streaming debate is over. The real question is how to value what Netflix has become.
The most significant structural change in Amazon's business is not in the headlines. It is in the gross margin line.
Services now generates over $85 billion annually at margins above 70 percent. Understanding what this means for Apple's long-term economics requires separating it from the hardware narrative.
Three interlocking advantages make Microsoft structurally difficult to displace, even as the AI landscape shifts the technology industry around it.
Azure is growing. Profits are growing. Free cash flow is going the wrong direction. Understanding why matters more than the headline numbers.
Revenue swings 50% with crypto prices. The question is whether the infrastructure layer Coinbase is building makes each cycle more valuable than the last.
The Supercharger network, Autopilot data, and OTA software are real advantages. At 332 times earnings, the market is pricing them as if they are already fully monetized.
AWS, advertising, and fulfillment are not three separate businesses. They are three interlocking moats that make Amazon's overall position stronger than any individual piece suggests.
Revenue grew 8x in two years. Operating margins hit 60%. The question isn't whether Nvidia has a moat, it's whether that moat is durable.
Nvidia's financials have undergone a transformation with few precedents in semiconductor history. The numbers tell a story the narrative alone cannot capture.